The Italian Rare Pancreatic Exocrine Cancer Initiative

Oronzo Brunetti, Claudio Luchini, Antonella Argentiero, Stefania Tommasi, Anita Mangia, Giuseppe Aprile, Paolo Marchetti, Enrico Vasile, Andrea Casadei Gardini, Mario Scartozzi, Sandro Barni, Sara Delfanti, Fernando De Vita, Francesco Di Costanzo, Michele Milella, Chiara Alessandra Cella, Rossana Berardi, Ivana Cataldo, Daniele Santini, Claudio DoglioniEvaristo Maiello, Rita T. Lawlor, Vincenzo Mazzaferro, Sara Lonardi, Felice Giuliante, Giovanni Brandi, Aldo Scarpa, Stefano Cascinu, Nicola Silvestris

Research output: Contribution to journalArticle

Abstract

Introduction: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. Methods: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway–oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. Conclusions: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.

Original languageEnglish
JournalTumori
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pancreatic Neoplasms
Carcinoma
Acinar Cell Carcinoma
Signet Ring Cell Carcinoma
Adenosquamous Carcinoma
Carcinosarcoma
Neoplasms
Medullary Carcinoma
Validation Studies
Osteoclasts
Advisory Committees
Giant Cells
Therapeutics
Computational Biology
Paraffin
In Situ Hybridization
Adenocarcinoma
Retrospective Studies
Immunohistochemistry
Genome

Keywords

  • biomolecular characterization
  • chemotherapy
  • pancreatic cancer
  • Rare tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Italian Rare Pancreatic Exocrine Cancer Initiative. / Brunetti, Oronzo; Luchini, Claudio; Argentiero, Antonella; Tommasi, Stefania; Mangia, Anita; Aprile, Giuseppe; Marchetti, Paolo; Vasile, Enrico; Casadei Gardini, Andrea; Scartozzi, Mario; Barni, Sandro; Delfanti, Sara; De Vita, Fernando; Di Costanzo, Francesco; Milella, Michele; Cella, Chiara Alessandra; Berardi, Rossana; Cataldo, Ivana; Santini, Daniele; Doglioni, Claudio; Maiello, Evaristo; Lawlor, Rita T.; Mazzaferro, Vincenzo; Lonardi, Sara; Giuliante, Felice; Brandi, Giovanni; Scarpa, Aldo; Cascinu, Stefano; Silvestris, Nicola.

In: Tumori, 01.01.2019.

Research output: Contribution to journalArticle

Brunetti, O, Luchini, C, Argentiero, A, Tommasi, S, Mangia, A, Aprile, G, Marchetti, P, Vasile, E, Casadei Gardini, A, Scartozzi, M, Barni, S, Delfanti, S, De Vita, F, Di Costanzo, F, Milella, M, Cella, CA, Berardi, R, Cataldo, I, Santini, D, Doglioni, C, Maiello, E, Lawlor, RT, Mazzaferro, V, Lonardi, S, Giuliante, F, Brandi, G, Scarpa, A, Cascinu, S & Silvestris, N 2019, 'The Italian Rare Pancreatic Exocrine Cancer Initiative', Tumori. https://doi.org/10.1177/0300891619839461
Brunetti, Oronzo ; Luchini, Claudio ; Argentiero, Antonella ; Tommasi, Stefania ; Mangia, Anita ; Aprile, Giuseppe ; Marchetti, Paolo ; Vasile, Enrico ; Casadei Gardini, Andrea ; Scartozzi, Mario ; Barni, Sandro ; Delfanti, Sara ; De Vita, Fernando ; Di Costanzo, Francesco ; Milella, Michele ; Cella, Chiara Alessandra ; Berardi, Rossana ; Cataldo, Ivana ; Santini, Daniele ; Doglioni, Claudio ; Maiello, Evaristo ; Lawlor, Rita T. ; Mazzaferro, Vincenzo ; Lonardi, Sara ; Giuliante, Felice ; Brandi, Giovanni ; Scarpa, Aldo ; Cascinu, Stefano ; Silvestris, Nicola. / The Italian Rare Pancreatic Exocrine Cancer Initiative. In: Tumori. 2019.
@article{c05c31e16907433ea8cb9eb6d00e962b,
title = "The Italian Rare Pancreatic Exocrine Cancer Initiative",
abstract = "Introduction: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85{\%} and 10{\%} of cases, respectively. The remaining 5{\%} are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. Methods: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway–oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. Conclusions: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.",
keywords = "biomolecular characterization, chemotherapy, pancreatic cancer, Rare tumors",
author = "Oronzo Brunetti and Claudio Luchini and Antonella Argentiero and Stefania Tommasi and Anita Mangia and Giuseppe Aprile and Paolo Marchetti and Enrico Vasile and {Casadei Gardini}, Andrea and Mario Scartozzi and Sandro Barni and Sara Delfanti and {De Vita}, Fernando and {Di Costanzo}, Francesco and Michele Milella and Cella, {Chiara Alessandra} and Rossana Berardi and Ivana Cataldo and Daniele Santini and Claudio Doglioni and Evaristo Maiello and Lawlor, {Rita T.} and Vincenzo Mazzaferro and Sara Lonardi and Felice Giuliante and Giovanni Brandi and Aldo Scarpa and Stefano Cascinu and Nicola Silvestris",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0300891619839461",
language = "English",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - The Italian Rare Pancreatic Exocrine Cancer Initiative

AU - Brunetti, Oronzo

AU - Luchini, Claudio

AU - Argentiero, Antonella

AU - Tommasi, Stefania

AU - Mangia, Anita

AU - Aprile, Giuseppe

AU - Marchetti, Paolo

AU - Vasile, Enrico

AU - Casadei Gardini, Andrea

AU - Scartozzi, Mario

AU - Barni, Sandro

AU - Delfanti, Sara

AU - De Vita, Fernando

AU - Di Costanzo, Francesco

AU - Milella, Michele

AU - Cella, Chiara Alessandra

AU - Berardi, Rossana

AU - Cataldo, Ivana

AU - Santini, Daniele

AU - Doglioni, Claudio

AU - Maiello, Evaristo

AU - Lawlor, Rita T.

AU - Mazzaferro, Vincenzo

AU - Lonardi, Sara

AU - Giuliante, Felice

AU - Brandi, Giovanni

AU - Scarpa, Aldo

AU - Cascinu, Stefano

AU - Silvestris, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. Methods: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway–oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. Conclusions: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.

AB - Introduction: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. Methods: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway–oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. Conclusions: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.

KW - biomolecular characterization

KW - chemotherapy

KW - pancreatic cancer

KW - Rare tumors

UR - http://www.scopus.com/inward/record.url?scp=85071076334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071076334&partnerID=8YFLogxK

U2 - 10.1177/0300891619839461

DO - 10.1177/0300891619839461

M3 - Article

C2 - 30967031

AN - SCOPUS:85071076334

JO - Tumori

JF - Tumori

SN - 0300-8916

ER -